icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Pfizer's (PFE.US) innovative cancer drug has applied for clinical trials in China for the first time, targeting KRAS mutation tumors.

Market IntelWednesday, Dec 4, 2024 10:40 pm ET
1min read

On December 5, the Center for Drug Evaluation (CDE) of China's National Administration for Drug Regulation's website announced that the clinical trial application of Pfizer's (PFE.US) new drug PF-07934040 had been accepted. According to public information, it is a KRAS pan-inhibitor under development by Pfizer, which is conducting a phase I clinical trial in the international community. This is the first time the product has applied for an IND in China, and the acceptance of PF-07934040's clinical application in China means that the product is expected to conduct clinical research in China soon.According to the information on Pfizer's website, PF-07934040 is a pan-KRAS "ON/OFF" inhibitor with activity against wild-type (wt) KRAS and major mutant subtypes, without activity against NRAS or HRAS. PF-07934040 shows binding to both the OFF (GDP-bound) and ON (GTP-loaded) states of KRAS wt, and the binding affinity to the mutants is very low, with a 5,000-fold selectivity for KRAS over HRAS/NRAS.Research has shown that PF-07934040 blocks the binding of RAF-RBD to GTP-loaded KRAS mutants, indicating that its mechanism of action may include binding to the ON state of KRAS and inhibiting the binding of RAF, regulating downstream signal transduction.According to ClinicalTrials.gov, Pfizer is conducting a phase I clinical study to evaluate the optimal dose, efficacy, and safety of PF-07934040 as a single agent or in combination with other targeted drugs in patients with KRAS gene mutations in advanced solid tumors. The study is planned to enroll 330 patients with non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, etc. in the international community.

Comments

Add a public comment...
Post
User avatar and name identifying the post author
therealchengarang
12/05
$PFE Out of all the stocks I own, only this one is not green this year, and it's supposed to be the safe one.
0
Reply
User avatar and name identifying the post author
Tech Novice
12/05
$PFE This person was seen looking for Albert B on 42nd street.
0
Reply
User avatar and name identifying the post author
DEBORAH SUE
12/05

Are you seeking for a reliable and profitable investment solution? Look no further! Cy Watson the CEO of Involio app is a seasoned trader with years of experience, I invite you to partner with him and unlock exceptional returns on your investments. He is available on @tradelivewithcy on telegram

0
Reply
User avatar and name identifying the post author
Electrical_Green_258
12/05
Holding $PFE long-term. Cancer drugs are goldmines. Diversify, but don't sleep on this one.
0
Reply
User avatar and name identifying the post author
QuantumQuicksilver
12/05
Holding $PFE long-term, potential game-changer here.
0
Reply
User avatar and name identifying the post author
S_H_R_O_O_M_S999
12/05
KRAS inhibitors could be the next big thing
0
Reply
User avatar and name identifying the post author
ImplementEither7716
12/05
Pfizer's move into China is a smart play
0
Reply
User avatar and name identifying the post author
JSOAN321
12/05
Pfizer's move into China is smart. Huge market, huge potential. 🌏
0
Reply
User avatar and name identifying the post author
Tiger_bomb_241
12/05
Pfizer's move into China's market is smart. KRAS inhibitors could be a game-changer. 🚀
0
Reply
User avatar and name identifying the post author
WoodKite
12/05
Pfizer's drug shows promise. But let's see those trial results. Keep expectations realistic.
0
Reply
User avatar and name identifying the post author
itsCblast
12/05
KRAS mutations are common. If Pfizer nails this, they'll dominate the oncology space.
0
Reply
User avatar and name identifying the post author
pimppapy
12/05
KRAS mutations are tough to target, but Pfizer's got a solid shot. Let's see how it plays out.
0
Reply
User avatar and name identifying the post author
Ben280301
12/05
China's regulatory green light is a big deal. Pfizer's in the right place at the right time.
0
Reply
User avatar and name identifying the post author
Interesting_Award_86
12/05
Pan-KRAS inhibitor? That's some next-level tech. Pfizer's not messing around.
0
Reply
User avatar and name identifying the post author
oakleystreetchi
12/05
Phase I trials are crucial. Pfizer's got 330 patients lined up. Bullish on their strategy.
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App